Comparative Pharmacology
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus NALLPEN.
DICLOXACILLIN SODIUM vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicloxacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and leading to cell lysis. It is resistant to penicillinase-producing organisms.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
125-500 mg orally every 6 hours
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates, elderly, or severe renal impairment.
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Primarily renal: ~60-85% unchanged via glomerular filtration and tubular secretion; ~10% hepatobiliary (bile) and fecal; minor metabolism to penicilloic acid.
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic